MX2019006326A - Derivados de tirosina y composiciones que los comprenden. - Google Patents
Derivados de tirosina y composiciones que los comprenden.Info
- Publication number
- MX2019006326A MX2019006326A MX2019006326A MX2019006326A MX2019006326A MX 2019006326 A MX2019006326 A MX 2019006326A MX 2019006326 A MX2019006326 A MX 2019006326A MX 2019006326 A MX2019006326 A MX 2019006326A MX 2019006326 A MX2019006326 A MX 2019006326A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- tyrosine hydroxylase
- hydroxylase inhibitor
- tyrosine derivatives
- subject
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000003667 tyrosine derivatives Chemical class 0.000 title 1
- 229940122110 Tyrosine hydroxylase inhibitor Drugs 0.000 abstract 4
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 230000004663 cell proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/365,120 US20170080093A1 (en) | 2013-10-22 | 2016-11-30 | Tyrosine Derivatives And Compositions Comprising Them |
| PCT/US2017/063865 WO2018102506A1 (en) | 2016-11-30 | 2017-11-30 | Tyrosine derivatives and compositions comprising them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019006326A true MX2019006326A (es) | 2019-07-12 |
Family
ID=60703174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006326A MX2019006326A (es) | 2016-11-30 | 2017-11-30 | Derivados de tirosina y composiciones que los comprenden. |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3548086A1 (enExample) |
| JP (2) | JP2019536783A (enExample) |
| KR (1) | KR20190089191A (enExample) |
| CN (1) | CN110062633A (enExample) |
| AU (1) | AU2017368135A1 (enExample) |
| BR (1) | BR112019011033A2 (enExample) |
| CA (1) | CA3045110A1 (enExample) |
| EA (1) | EA201991305A1 (enExample) |
| IL (1) | IL266840A (enExample) |
| MX (1) | MX2019006326A (enExample) |
| PH (1) | PH12019501186A1 (enExample) |
| WO (1) | WO2018102506A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111743887A (zh) * | 2019-03-26 | 2020-10-09 | 深圳先进技术研究院 | α-甲基酪氨酸或其衍生物的用途 |
| CN114173578A (zh) | 2019-05-14 | 2022-03-11 | 迪美公司 | 用于治疗癌症的组合物和方法 |
| CA3157334A1 (en) * | 2019-11-07 | 2021-05-14 | Miguel Angel MOLINA-VILLA | Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors |
| US20210220312A1 (en) * | 2020-01-17 | 2021-07-22 | Tyme, Inc. | Compositions And Methods For Modulating Cancer |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI323662B (en) * | 2002-11-15 | 2010-04-21 | Telik Inc | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
| EP1718145A4 (en) * | 2004-02-02 | 2012-03-07 | Biosight Ltd | CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS |
| WO2007120153A1 (en) * | 2006-04-19 | 2007-10-25 | The Board Of Regents Of The University Of Texas System | Compositions and methods for cellular imaging and therapy |
| CN104586832B (zh) * | 2007-09-10 | 2018-02-16 | 北京强新生物科技有限公司 | 用于癌症治疗的组合物和方法 |
| NZ628757A (en) * | 2012-01-17 | 2016-07-29 | Tyme Inc | Pharmaceutical compositions and methods for treating cancer |
| US9585841B2 (en) * | 2013-10-22 | 2017-03-07 | Tyme, Inc. | Tyrosine derivatives and compositions comprising them |
-
2017
- 2017-11-30 JP JP2019528632A patent/JP2019536783A/ja active Pending
- 2017-11-30 MX MX2019006326A patent/MX2019006326A/es unknown
- 2017-11-30 BR BR112019011033A patent/BR112019011033A2/pt not_active IP Right Cessation
- 2017-11-30 EP EP17817552.7A patent/EP3548086A1/en not_active Withdrawn
- 2017-11-30 AU AU2017368135A patent/AU2017368135A1/en not_active Abandoned
- 2017-11-30 WO PCT/US2017/063865 patent/WO2018102506A1/en not_active Ceased
- 2017-11-30 CA CA3045110A patent/CA3045110A1/en active Pending
- 2017-11-30 CN CN201780074235.7A patent/CN110062633A/zh active Pending
- 2017-11-30 EA EA201991305A patent/EA201991305A1/ru unknown
- 2017-11-30 KR KR1020197018473A patent/KR20190089191A/ko not_active Ceased
-
2019
- 2019-05-23 IL IL266840A patent/IL266840A/en unknown
- 2019-05-29 PH PH12019501186A patent/PH12019501186A1/en unknown
-
2022
- 2022-08-01 JP JP2022122538A patent/JP2022153587A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| PH12019501186A1 (en) | 2020-02-10 |
| KR20190089191A (ko) | 2019-07-30 |
| CN110062633A (zh) | 2019-07-26 |
| WO2018102506A1 (en) | 2018-06-07 |
| JP2022153587A (ja) | 2022-10-12 |
| JP2019536783A (ja) | 2019-12-19 |
| EA201991305A1 (ru) | 2019-10-31 |
| AU2017368135A1 (en) | 2019-06-13 |
| EP3548086A1 (en) | 2019-10-09 |
| IL266840A (en) | 2019-07-31 |
| BR112019011033A2 (pt) | 2019-10-15 |
| CA3045110A1 (en) | 2018-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
| PH12019501186A1 (en) | Tyrosine derivatives and composition comprising them | |
| PH12019502379A1 (en) | Pd-1/pd-l1 inhibitors | |
| MY195110A (en) | Antibodies to PD-1 and uses Thereof | |
| MX2022012937A (es) | Conjugados de afinidad-oligonucleotido y usos de los mismos. | |
| EP4458418A3 (en) | Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer | |
| WO2019067666A8 (en) | Therapeutic methods relating to hsp90 inhibitors | |
| CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
| MY199019A (en) | Pd-1 antibodies | |
| WO2015002724A3 (en) | SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | |
| EP4613332A3 (en) | Cot modulators and methods of use thereof | |
| TWD173671S (zh) | 通訊耳機之部分 | |
| AU2017260389A1 (en) | Chimeric neurotoxins | |
| EP4389142A3 (en) | Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia | |
| CR20110553A (es) | Terapia complementaria contra el cáncer | |
| MX2015013177A (es) | Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki. | |
| WO2017132746A8 (en) | Ubiquitin variants and uses thereof as 53bp1 inhibitors | |
| WO2015181624A3 (en) | Nucleoside derivatives for the treatment of cancer | |
| MX2017011521A (es) | Composiciones topicas que comprenden un corticosteroide. | |
| MX2019013642A (es) | Compuestos, composiciones y metodos. | |
| MX2021008839A (es) | Composiciones aglomerantes y metodos para fabricacion y uso de las mismas. | |
| CA3056612A1 (en) | Analogs of deutetrabenazine, their preparation and use | |
| MX380547B (es) | Composición que comprende un inhibidor de fgfr1/kdr micronizado y el uso del mismo en el tratamiento de tumores neuroendocrinos. | |
| GB2543709A (en) | Pharmaceutical agent |